Hydronephrosis Treatment Market Analysis

Hydronephrosis Treatment Market Analysis

To get key market trends

  Download Free Sample

Based on type, the market is segmented into unilateral hydronephrosis and bilateral hydronephrosis. The unilateral hydronephrosis segment held leading revenue share in 2023 and is anticipated to reach over USD 2.9 billion by 2032.
 

• Structural abnormalities in the urinary tract, such as ureteropelvic junction (UPJ) obstruction or ureteral strictures, can lead to unilateral hydronephrosis. The prevalence of such abnormalities contributes to the rising demand for treatment in this segment.  
   
• Moreover, variations in healthcare provider practices, including diagnostic approaches, treatment protocols, and follow-up care, may impact the demand for treatment in the unilateral hydronephrosis segment.
   

Based on indications, the hydronephrosis treatment market is segmented into intrinsic and extrinsic. The intrinsic segment held leading revenue share in 2023 and is anticipated to reach USD 3.4 billion by 2032.
 

• Conditions such as kidney stones, urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), pelvic tumors, and congenital abnormalities are common underlying causes of hydronephrosis. The growing incidence of these conditions contributes to the segmental growth.
   
• Moreover, sedentary lifestyles, poor dietary habits, and increased consumption of processed foods contribute to the development of conditions such as kidney stones and urinary tract infections. Lifestyle factors plays a significant role in driving the incidence of hydronephrosis-related conditions, thus, driving the industry growth.  
   

Based on diagnosis, the hydronephrosis treatment market is segmented into laboratory tests and imaging. The imaging segment held leading revenue share in 2023 and was valued at USD 1.4 billion.
 

• Imaging techniques are generally non-invasive, making them preferred options for diagnosing hydronephrosis, especially in pediatric and geriatric populations or individuals with comorbidities who may be at increased risk from invasive procedure. 
   
• Moreover, patients often prefer non-invasive imaging techniques due to their comfort and convenience compared to invasive procedures. This preference drives the demand for imaging modalities in the diagnosis and management of hydronephrosis.
   

Based on treatment, the hydronephrosis treatment market is segmented into shock wave lithotripsy, laparoscopy, bladder catheterization, steroid therapy, other treatments. The shock wave lithotripsy segment held leading revenue share of around 34.9% in 2023 and is anticipated to witness robust growth.
 

• Compared to surgical procedures such as ureteroscopy or percutaneous nephrolithotomy (PCNL), SWL typically involves minimal discomfort and has a shorter recovery time. Patients can often resume normal activities shortly after the procedure, leading to increased patient satisfaction and demand.
   
• The global incidence of kidney stones is increasing, driven by factors such as dietary habits, dehydration, obesity, and metabolic disorders. As the incidence of kidney stones rises, so does the demand for effective treatment options like SWL.
   

The hydronephrosis treatment market by age-group is categorized into adult and pediatric. The pediatric segment held significant market share in 2023 and is expected to reach around USD 1.2 billion by 2032.
 

• Many cases of pediatric hydronephrosis are congenital, meaning they are present at birth due to structural abnormalities or urinary tract malformations. The prevalence of congenital hydronephrosis contributes to the segment growth.
   
• Moreover, advances in prenatal imaging techniques and widespread adoption of prenatal screening programs allow for early detection of hydronephrosis during pregnancy. Prenatal diagnosis enables timely intervention and treatment planning, thereby, increasing the demand for pediatric treatment options.
   

North America hydronephrosis treatment market accounted for around USD 1 Billion revenue in 2023 and is predicted to witness substantial market growth.
 

• North America has well-developed healthcare infrastructure, including modern hospitals, specialized clinics, and advanced diagnostic and treatment facilities. Access to state-of-the-art medical technology and expertise enhances the diagnosis and management of hydronephrosis, contributing to increased demand for treatment.
   
• Furthermore, obesity and diabetes are significant risk factors for the development of kidney stones and other urinary tract conditions. North America has a high prevalence of obesity and diabetes, contributing to the increased incidence of hydronephrosis, thus, driving the demand for treatment.